Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed biliary tract or gallbladder cancer that have relapsed or are refractory after one prior gemcitabine-based chemotherapy regimen for advanced biliary cancer~* Evaluable disease~* ECOG PS ≤ 2~* Adequate bone marrow, liver and renal function~Exclusion Criteria:~* Treatment with more than one prior chemotherapy regimen~* Known, uncontrolled CNS metastases~* Baseline peripheral neuropathy ≥ grade 2.~* Significant circulatory disorders in the past 6 months~* Concomitant use of phosphodiesterase inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SPI-1620 & Docetaxel (Type: EXPERIMENTAL): Patients will receive 11 μg/m2 of SPI-1620 intravenously over one minute. Ten minutes after (±2 min) SPI-1620 administration, patients will receive docetaxel 75 mg/m2 intravenous. This regimen will be repeated every 3-weeks cycles until progression or intolerable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).